JNJ ▲ +0.4% - Johnson & Johnson $JNJ - RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026 Johnson & Johnson shares rose 0.4% following positive clinical data presented at the World Conference on Lung Cancer showing that its combination therapy of RYBREVANT FASPRO and LAZCLUZE demonstrated low rates of treatment-related adverse events. The favorable safety profile supports the potential of the drug combination, which targets EGFR-mutant non-small cell lung cancer patients. 14-SEP-2026 11:00 PM ET